The results of a large-scale, real-world study released on Monday showed that two doses of the COVID-19 vaccine from Pfizer and BioNTech can provide powerful protection in just one injection to prevent infection and possibly prevent people from spreading the virus.
Public Health England (PHE) said in a press release on Monday: “One dose can reduce the risk of infection by more than 70%, and after the second dose it can increase to 85%.” “This suggests that the vaccine may also help interruption. The spread of the virus, because if there is no infection, the virus cannot be spread.”
The author of the study said that starting from the 1
According to the authors, the results of the study show that Pfizer’s vaccine can fight against a variant of the coronavirus called B.1.1.7 in the UK, which was very popular in the UK during the study period.
According to estimates by the Centers for Disease Control and Prevention (CDC), B.1.1.7 is more infectious and has spread to all parts of the world, including 44 states in the United States.
Data from the Centers for Disease Control and Prevention (CDC) show that Pfizer has so far delivered 32.8 million doses in the United States.
PHE’s ongoing SIREN study has conducted a two-month follow-up survey of more than 23,000 British medical staff, regardless of whether they have symptoms or not, they will be tested for COVID-19 every week. They conduct laboratory polymerase chain reaction (PCR) tests every two weeks, gold standard tests and rapid antigen tests twice a week.
Then, the study confirmed the length of time to be infected with COVID-19 through PCR and compared vaccinated and unvaccinated people. Frequent testing means that researchers can pick out asymptomatic people who are infected with the virus, and they use it as a “transmission vector”-one-third of coronavirus patients are asymptomatic, but can be unaware spread.
The study is a preprint, waiting for other experts to carefully study its methods and conclusions, and then published in the “Lancet” medical journal.
Another study on Israeli health workers published on February 18 in the journal The Lancet found that Pfizer’s vaccine was effective in preventing symptomatic infections 15-28 days after the first injection, but did not evaluate Symptoms spread.
The age of the participants in the SIREN study is working age, most of them are white women, and three-quarters of the patients do not have coexisting medical conditions, so the study results may not be generalized to the general population or the elderly.
PHE said in a press release that early data from routine testing showed that one dose of Pfizer’s injection is 57% effective in preventing symptomatic COVID-19 in people over 80, and the second dose can be increased to more than 85%.
This effect appears about three to four weeks after the first dose. Compared with the results of the SIREN study, the lower efficacy numbers may be due to the poorer response of the immune system to vaccines as we age. Among those who supplemented the Pfizer-BioNTech vaccine, hospitalizations and deaths from COVID-19 were reduced by more than 75%.
A study in Scotland reported similar findings on Monday. This study looked at the hospitalization rate after immunization and found that Pfizer’s injection vaccine reduced the hospitalization rate by as much as 85% after 4 weeks of the first dose.
Dr. Mary Ramsay, head of PHE immunization. He said there is “strong evidence” that the Pfizer-BioNTech vaccine is preventing people from being infected, while also preventing hospitalization and death.